secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-06-01T10:20:20+00:00
Accession:  0001213900-26-063125
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Immunotherapeutics signs commercial supply and capacity agreements with Vetter for sonelokimab
--------------------------------------------------------------------------------

- Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.
- Capacity Agreement commits MoonLake to binding annual minimum and maximum quantity orders; failure may trigger compensation.
- Agreements include pricing adjustment provisions based on Vetter’s cost increases and change-of-control termination rights.
- Sonelokimab is MoonLake’s key product candidate; deal supports potential commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026063125/0001213900-26-063125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026063125/ea0292693-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-063125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer